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Abstract
Objective:  To determine the accuracy of the contemporary Epstein criteria for predicting insignificant and
organ-confined prostate cancer in a North African ethnic group of patients who were eligible for active
surveillance based on these criteria, but had been subjected to radical prostatectomy.
Patients and  methods:  A total of 340 North African men underwent radical prostatectomy for clinically
localized prostate cancer at two academic institutions between January 2006 and September 2013. In 74Upstaging;
North Africa
of these patients (21.76%), prostate cancer had been assumed to be insignificant based on the contem-
porary Epstein criteria. The radical prostatectomy specimens were analyzed in order to identify the rate
prostate cancer, defined as either pathologic Gleason score 7–10 and/or a
on-organ-confined disease (stage ≥  pT3a and/or pN1 and/or positive surgicalof pathologically unfavorable 
tumor volume > 0.5 cc, and/or n
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Results:  Gleason sum upgrading (≥7) was necessary in 16 (21.6%) and upstaging of the radical prosta-
tectomy specimens in 18 patients (24.3%). Simultaneous upstaging and upgrading of the specimens was
observed in 12 patients (16%). A tumor volume ≤  0.5 cc was found in 42 patients (57%). The rate of mul-
tifocality of prostate cancer (≥2 foci) was 59.5%. The accuracy of the contemporary Epstein criteria for
predicting insignificant prostate cancer was 57%, while it predicted organ-confined disease in 85%.
Conclusion:  The contemporary Epstein criteria used for the identification of clinically insignificant prostate
cancer have been found to underestimate the real state of prostate cancer in as many as 43% of our
patients. They were a good tool for predicting organ-confined rather than insignificant prostate cancer
in our North African patients. Therefore, caution is advised when the decision on the implementation of
active surveillance or focal therapy is solely based on these criteria.
© 2016 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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embedded separately in multiple containers. The biopsy and radicalIntroduction
As a consequence of the widespread use of assessment of the
prostate-specific antigen (PSA) and digital rectal examination
(DRE) in combination with extended-core prostate biopsy strate-
gies, there is some concern about the risk of overdiagnosis and
overtreatment of some forms of prostate cancer which have a
protracted natural history and pose little threat to the patients dur-
ing their lifetime. Stage migration resulting from aggressive PSA
screening has progressively increased the proportion of patients who
fall into the “favorable-risk” category; they now account for more
than half of all newly diagnosed prostate cancer (PCa) patients in
western countries [1–4]. As a consequence, the concept of insignifi-
cant prostate cancer (Ins-PCa) has progressively emerged in the last
two decades, and alternative treatment options for these patients
such as active surveillance (AS) and organ-sparing focal therapies
(FT) have been implemented. However, the major obstacle to the
widespread use of these conservative therapies remains the diffi-
culty in precisely identifying low-risk PCa patients based on their
pre-treatment clinical and pathologic features only [5,6].
For the period 2010–2019 Morocco has adopted the National Plan
for Prevention and Cancer Control (NPPCC). The mean goal of
the NPPCC is to reduce cancer-related morbidity and mortality
and to improve the patients’ quality of life. However, data on PCa
in Moroccan men are rare, and there is only a limited number
of studies providing relevant epidemiologic and prognostic infor-
mation. According to the cancer registries of the cities of Rabat
(2006–2008) and Casablanca (2004–2007), PCa is the second most
common malignancy in Moroccan men (10.5–15.5%) after lung
cancer (19.1–22.1%) [7,8]. The age-standardized incidence rate
(ASIR) and the age-standardized mortality rate (ASMR) of PCa
in Morocco (18.5 per 100,000 and 12.9 per 100,000, respectively,
based on GLOBOCAN 2012 data [9]), have constantly increased
during the last decades and are among the highest in the Middle East
and North Africa (MENA Region). In contrast to western and devel-
oped countries where nowadays the usefulness of PSA screening is
being questioned, the upward trends in incidence and mortality due
to PCa and the high rate of advanced disease in newly diagnosed
patients in Morocco and the MENA region will inevitably result
in a widespread use of PSA screening and extended-core prostate
biopsy. However, in the near future, practitioners in this region of
the world will also be increasingly confronted with the problem of
how to manage low-risk PCa. The Epstein criteria are among the
p
r
uost commonly used tools to identify patients with Ins-PCa who
ill be eligible for AS [10].
ur aim is to determine the accuracy of the contemporary Epstein
riteria in predicting Ins-PCa and organ-confined disease in a North
frican ethnic group of patients who were eligible to AS according
o these criteria but were treated with radical prostatectomy (RP).
ubjects  and  methods
atient  population
n total, 340 radical prostatectomies were performed at two aca-
emic Moroccan institutions (Mohammed V Military Hospital of
abat and Moulay Ismail Military Hospital of Meknes) between
anuary 2006 and September 2013. Out of this group, 74 patients
21.7%) fulfilled the contemporary Epstein criteria for clinically
ns-PCa after extended 10–18 core prostate biopsy: stage T1c, PSA
ensity ≤  0.15, Gleason score ≤  6, fewer than three biopsies with
rostate cancer, and up to 50% of cancer involvement in any core.
he data of these patients were reviewed in order to assess the rate of
nfavorable PCa patterns in the prostatectomy specimens. Unfavor-
ble pathologic characteristics were defined as a Gleason sum > 6
7–10) and/or non-organ-confined disease and/or a tumor vol-
me > 0.5 cc. Non-organ-confined disease included extraprostatic
xtension, a stage ≥  pT3a and/or lymph-node involvement and/or
ositive surgical margins. Ins-PCa was defined as organ-confined
isease, a tumor volume ≤  0.5 cc and a Gleason sum ≤  6.
linical  and  pathological  evaluation
he clinical stage was assigned according to the 2002 TNM stag-
ng system, and pre-treatment PSA was measured before DRE and
ransrectal ultrasonography (TRUS). None of the patients received
eoadjuvant androgen deprivation therapy. The prostate volume was
ssessed using TRUS with a 7.5-MHz ultrasound probe (General
lectric Healthcare, Milwaukee, USA). PSA density was calcu-
ated by dividing the PSA value by the prostate volume measured
n TRUS. Biopsy cores were obtained under TRUS guidance androstatectomy specimens were staged and graded by three expe-
ienced genitourinary pathologists (A.AB., F. G. and S. M) who
sed standardized protocols and reporting templates. The extent of
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Table  1  Descriptive characteristics of 74 North African men who
fulfilled the Epstein clinically insignificant prostate cancer criteria
before RP.
Variable Value
Total population 74
Age (yr)
Mean ± SD (median) 63 ± 4.546 (64.1)
Range 49–76
Preoperative PSA (ng/mL)
Mean ± SD (median) 6.7 ± 1.6749 (5.7)
Range 2.1–20
Prostate volume (cm3)
Mean ± SD (median) 58 ± 33.57 (63.67)
Range 25–130
PSA density
Mean ± SD (median) 0.08 ± 0.06 (0.08)
Range 0.03–0.15
No. of cores per biopsy
Mean ± SD (median) 13.5 ± 2.6 (12.2)
Range 10–18
No. of positive cores: No. (%)
•1 54 (73%)
•2 20 (27%)
% of cancer/positive core
Mean ± SD (median) 10.1 ± 8.5 (7.0)
Range 0.5–45.0
Biopsy Gleason sum: No. (%)
• <6 5 (6.7%)
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Table  2  Pathologic findings at radical prostatectomy (RP)
specimen.
Variable No. of patients (%)
Total patients 74 (100%)
Tumor volume at RP specimen
• ≤ 0.5 cc 42 (57%)
• 0.5–1.3 cc 14 (19%)
• >1.3 cc 6 (8%)
• Not reported 12 (16%)
Tumor focality
• Unifocal 30 (40.5%)
• ≥2 foci 44 (59.5%)
Pathological Gleason sum
• ≤6 58 (78.3%)
• 7 (3 + 4) 13 (17.6%)
• 7 (4 + 3) 2 (2.7%)
• 8 1 (1.3%)
• 9 0
• 10 0
Gleason sum upgrading at RP specimen 16 (21.6%)
Upstaging at RP specimens
• Total 18 (24.3%)
• Stage pT2b 5 (6.7%)
• Stage pT2c 2 (2.7%)
• Non organ confined disease
© Total 11 (15%)
© Stage pT3a 8 (72.7%)
© SVI 3 (27%)
© LNI 1 (9%)
© PSM 3 (27%)
Both upstaging and upgrading at RP specimen 12 (16%)
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s• =6 69 (93.3%)
PSA, prostate specific antigen; SD, standard deviation.
ancer invasion on the biopsy core was calculated based on the sum
f all the tumor foci, excluding benign prostate tissue. The percent-
ge of cancer in a positive biopsy core was calculated based on the
atio of the length of the cancer foci/total core length.
athologically, the prostatectomy specimens were included as a
hole according to the Stanford protocol. The Gleason score,
umber of tumor foci and tumor volume, extraprostatic extension,
eminal vesicle invasion, lymph node involvement, and the status of
he surgical margins were evaluated for each prostatectomy piece.
he tumor volume in the prostatectomy specimens was estimated
ased on the dominant tumor nodule, using the three-dimensional
uboid method described by Chen et al. [11] (tumor vol-
me = k(0.4) ×  length ×  width ×  thickness).
tatistical  analysis
e used the IBM SPSS statistics version 20 to perform a descrip-
ive and categorical analysis of the data. The accuracy of the
pstein criteria in predicting insignificant or organ-confined PCa
as assessed using Fisher’s exact test (significance at p  < 0.05).esults
he descriptive characteristics of the 74 North African men who
ulfilled the Epstein criteria for clinically Ins-PCa before RP are
E
n
8ummarized in Table 1. Table 2 summarizes the pathologic findings
f the prostatectomy specimens.
n upgrading of the Gleason sum was necessary in 16 patients
21.6%). The final Gleason score was 7 in 15 patients (20.3%)
nd 8 in one patient (1.3%). The final pathology results did not
eveal a Gleason pattern of 5 in any patient. Upstaging of the
rostatectomy specimens occurred in 18 patients (24.3%), while
he disease remained organ-confined (stages pT2b and pT2c) in 7
atients (9.4%). Non-organ-confined disease was seen in 11 patients
15%) with a pathologic stage of pT3a in most cases (72.7%).
eminal vesicle involvement (pT3b) was seen in 3 patients; in
ne of them final pathology also revealed lymph node involve-
ent. Positive surgical margins were observed in 3 patients, two
ith a pathological stage pT3b (seminal vesicle involvement) and
ne with stage pT3a disease. Simultaneous upstaging and upgrad-
ng of the prostatectomy specimens was observed in 12 patients
16%). The tumor volume in the prostatectomy specimen was
0.5 cc in 42 (57%), 0.5–2 cc in 14 (19%) and >2 cc in 6 patients
8%). No tumor involvement was seen in the prostatectomy spec-
mens of 12 patients (16%). The rate of multifocality of PCa
≥2 foci) was 59.5%. The accuracy of the contemporary Epstein
riteria in predicting Ins-PCa (organ-confined disease, Gleason
core ≤  6 and tumor volume ≤  0.5 cc) was 57%. The accuracy of
pstein criteria in predicting organ-confined disease (stage < pT3a,
o lymph node involvement, any tumor volume, any grade) was
5% (Table 3).
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Table  3  The accuracy of the contemporary Epstein criteria to predict the presence of insignificant and organ-confined disease at RP specimen
in North African man.
Fulfilled contemporary Epstein criteria* Total Insignificant PCa** Organ-confined disease***
n (%) p value n (%) p value
Yes 74 42 (57%) <0.0001 63 (85%) <0.0001
No 266 23 (8.6%) 202 (76%)
* Contemporary Epstein criteria: Stage T1c, PSA density ≤ 0.15 ng/mL per gram, Gleason score ≤ 6, fewer than three positive cores, and <50% of
cancer involvement in any core.
or vol
ositiv
c
s
i
t
n
G
d
t
n
p
w
d
E
O
b
s
c
o
u
i
u
c
t
p
found that PCa patients with a tumor volume ranging from 0.5 cc to** Insignificant PCa: organ-confined disease, Gleason score ≤6 and tum
*** Organ-confined-disease: Stage < pT3a, No lymphnodes invasion, No p
Discussion
The management of low-risk organ-confined disease, especially
in the subgroup of patients with presumed Ins-PCa, remains one
of the most challenging problems in modern onco-urology. Cur-
rently, there is still a lack in pre-treatment diagnostic tools that can
clearly distinguish significant from insignificant PCa. The contem-
porary Epstein criteria for clinically Ins-PCA, initially applied in
the USA to a population group mainly consisting of Caucasians
(over 95%) [10,12], are among the most commonly used tools to
identify patients with Ins-PCa and, thus, eligible to active surveil-
lance (AS). In the last decades, these criteria have gained interest
worldwide, and several studies have been carried out to evaluate
their accuracy in predicting low-risk PCa in different ethnic groups.
However, the reported accuracy varies widely: 84% in the USA
[12] with lower negative predictive values in African Americans
(48.4%) [13], 76% in Europe [14], 54.3% in the Middle East [15]
and 69.5% in Korea [16] (Table 4). Our study of a cohort of 74 North
African men shows that the Epstein criteria were accurate in predict-
ing Ins-PCa (organ confined disease, Gleason sum ≤  6 and tumor
volume ≤  0.5 cc) in 57% and organ-confined disease (stage < pT3a,
no lymph node involvement, any tumor volume, any grade) in 85%.
Many objective factors may explain the low accuracy of the Epstein
criteria for predicting Ins-PCa in North African men compared to
other ethnic groups. A tumor volume threshold of <0.5 cc in prosta-
tectomy specimens is one of the most important criteria for the
definition of Ins-PC as suggested by Stamey et al. [17]. The tumor
volume is of prognostic significance on univariate analysis and
1
c
d
Table  4  Accuracy of the contemporary Epstein criteria to predict Ins-PC
Characteristics Our North African
study
Middle eastern study
[15]
A
Fulfilled
Contemporary
Epstein criteria:
No. (%)
74/340 (21.76%) 35/70 (50%) 13
Study period 2006–2013 2000–2008 20
Postoperative Gleason sum: N (%)
• ≤6 56 (75.67%) 19 (54.28%) 91
• =7 17 (22.97%) 11 (31.42%) 40
• >7 1 (1.35%) 5 (14.28%) 0 
Upgraded 16 (21.62%) 2 (5.71%) – 
Undergraded 0 14 40
Organ-confined 63 (85%) 28 (80%) 12
Overall Ins-PCa 57% 54% 69ume ≤ 0.5 cc.
e surgical margins, any tumor volume, any grade.
orrelates closely with the Gleason score, stage and surgical margin
tatus of RP specimens, but there is still a lack of evidence about its
ndependent prognostic significance in multivariate studies [18]. In
he majority of studies on Epstein criteria validation, the cancer sig-
ificance was determined only by the organ-confined status and the
leason score. The inclusion of the tumor volume would probably
ecrease the number of Ins-PCa in these studies and further reduce
he overall accuracy of the Epstein criteria. In our study, there was
o report on any form of tumor volume measurement in16% of our
atients which is why they were excluded from the group of patients
ith assumed Ins-PCa. The exclusion of the tumor volume from the
efnition of Ins-PCa would naturally increase the accuracy of the
pstein criteria in our study from 57% to 78.3%.
n the other hand, the tumor volume threshold of <0.5 cc suggested
y Stamey et al. for the definition of Ins-PCa and used for the
election of the ideal candidates for AS in many protocols is being
hallenged by a number of authors. In a study cohort similar to that
f Stamey et al., Wolters et al. [19] introduced an updated tumor vol-
me threshold for the definition of Ins-PCa. They concluded that,
n cases of organ-confined PCa without Gleason patterns 4–5, the
se of a tumor volume of 1.3 cc could decrease the rate of mis-
lassification for AS selection. Based on this threshold (<1.3 cc),
he accuracy of the Epstein criteria in predicting Ins-PCa in our
atients will increase by 19%. In another recent study, Lee et al. [20].3 cc and a Gleason grade of 4/5 showed an increased risk of bio-
hemical recurrence, even when they suffered from organ-confined
isease and had a preoperative PSA level < 10 ng/mL. Moreover,
a around the world.
sian study [16] European study[14] North American study
[12]
1/1011 (12.95%) 366/2580 (14.18%) 237/237 (100%)
04–2009 1994–2006 2000–2003
 (69.46%) 278 (75.95%) 214 (90.29%)
 (30.53%) 88 (24.04%) 21 (8.86%)
0 2 (0.84%)
2 (0.54%) 1 (0.42%)
 88 23
9 (96.9%) 336 (91.8%) 217 (91.6%)
.5% 76% 84%
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lthough recent reports suggest that multiparametric magnetic res-
nance imaging (MP-MRI) may be more reliable for evaluating a
umor volume > 0.5 cc [21], it is difficult to predict the absence of
 high Gleason grade, even with more extended biopsy protocols.
s it is still unclear which clinical tumor volume threshold is the
est parameter to be used for AS selection and monitoring, we did
ot recommend an extended tumor volume (more than 0.5 cc) to be
sed for the definition of Ins-PCa in our patient cohort.
he threshold of 50% cancer involvement in the biopsy cores used
n the modified Epstein criteria has substituted the absence of bilat-
ral cancer used in the original study as an indicator of insignificant
ancer on biopsy. However, not infrequently, a prostate biopsy may
ontain two or more cancer foci separated by a stretch of interven-
ng benign tissue. Currently, there is no consensus as to the optimal
ethod for measuring the extent or percentage of cancer in such
ases. In the original study introducing the Epstein criteria, the can-
er, when discontinuous, was measured from one end to the other
s opposed to the measurement of the individual separate foci of
ancer excluding the benign prostate tissue in between. Although,
n a multivariate analysis, Karram et al. [22] found that measuring
he entire stretch of cancer foci was more predictive of stage and
argins than ignoring the benign tissue in between, measuring two
istinct tumor foci on a needle biopsy may provide implications
bout whether the criteria for Ins-PCa may be applied. Measuring
he two foci of cancer as if they were one single continuous focus
ay increase the percentage of tumor involvement to more than
0% and, therefore, will reduce the already low proportion of men
ulfilling the Epstein criteria and being eligible to AS.
n our study, the percentage of cancer involvement was estimated by
xcluding the benign tissue in between. Nevertheless, the accuracy
f Epstein criteria in predicting Ins-PCa was among the lowest in
he world. Similar to the rate reported for African-Americans [13],
wo scenarios may explain the high proportion of prostate cancer
ncorrectly classified as insignificant in our patients. The first is a
igh incidence of anterior zone tumors in North Africans. Anterior
one cancer is known to have fewer positive and less involved cores
hen using the 12-core biopsy technique. The second is the presence
f small-volume high-grade tumors in the peripheral zone that are
ot likely to be sampled on prostate biopsy due to their small size.
owever, the latter hypothesis is less evident, since the rate of high-
rade tumors in our study was 21.6%, mostly Gleason 3 + 4 or 4 + 3
20.3%), but without Gleason pattern 5 at final pathology.
o overcome this problem, we believe that North African men
ssigned to AS based on the contemporary Epstein criteria for
linically Ins-PCa may need to be followed with a 14-core biopsy
ampling the anterior zone and with MP-MRI.
ur study shows the highest incidence of Gleason upgrading in
atients who fulfilled the contemporary Epstein criteria (21.62%
ersus 0.42–5.71% in other studies). Modifications introduced by
he International Society of Urological Pathology (ISUP) Consen-
us Conference in 2005 on Gleason scoring have resulted in an
pgrading of certain pathological features of tumors with a Gleason
attern 3–4 [23]. However, none of the validation studies on the
pstein criteria indicate which Gleason system was in use. Thus,
ost of these studies did not apply the criteria in a proper way,
hich leads to a lack of valuable validation results, regardless of the
SUP Gleason score updates. The abrupt change in the predictive
alue of the Gleason score and the overall significance of cancer
s
o
m
pA. Ammani et al.
fter 2005 (Table 4) suggest that the Gleason grading system is, at
east partly, responsible for discrepancies between studies.
ur results are nearly similar to those of Hekal et al. [15], who
lso found a decreased accuracy of the contemporary Epstein crite-
ia in predicting Ins-PCa in a Middle Eastern population (57%
s. 54%). Comparable demographic, ethnic, economic and socio-
ultural characteristics between most countries of the MENA region
ay suggest the presence of possible links with a high aggressive-
ess of prostate cancer in this area. Moreover, limited data on PCa
n the MENA region have led to reports of more advanced-stage
isease at diagnosis in contrast to a high incidence of low-risk
rgan-confined PCa in most western countries [7,8,24–26]. How-
ver, in several western studies [27–30], the incidence of PCa was
ow among immigrants from the MENA region, and their prognosis
as significantly better than that of Caucasians and Blacks. In these
tudies, the incidence of prostate cancer was found to be higher
n immigrants from the MENA region compared to that reported
n the native populations, but it was still lower than the incidence
f prostate cancer seen in other ethnic groups. The inconsistency
n PCa features between immigrants from the MENA region and
embers of the native population may be attributed to environmen-
al, socio-cultural and professional factors as well as to the health
are systems rather than to an increased ethnic risk of developing
ggressive PCa.
ultifocality of PCa has been demonstrated to be frequent, varying
etween 60% and 90% of all cases [31]. In our study, PCa was mul-
ifocal in 59.5% of patients who fulfilled the contemporary Epstein
riteria.
he real impact of PCa multifocality on the risks of upstaging and
pgrading and the long-term biochemical recurrence rate remains
nclear. To date, the index tumor (as measured by its largest volume)
s presumed to be the driver of prognosis in most cases of multifo-
al PCa. Innovations in genetics and medical imaging including
-dimensional computed tomography (3D-CT) and MP-MRI will
robably increase our ability to establish the prognosis and topo-
raphical extent of all cancer foci within a prostate, leading to more
recise therapeutic decisions, especially in determining candidates
ligible to minimally-invasive therapies like AS and focal therapy.
31,32].
ur study shows that the contemporary Epstein criteria are not suf-
cient to be used clinically for predicting insignificant (as opposed
o organ-confined) PCa in North African men. Thus, we believe that
here is a need to re-update these criteria by adding novel tools like
ovel markers and MP-MRI in order to improve their predictive
alue for indolent PCa and to identify patients who can be safely
nrolled in an active surveillance procedure.
he present study has several limitations. First, this is a retrospective
tudy with a relatively small number of patients from one country
nly, which may not be representative of the whole population of
orth Africa. Second, we were not able to precisely define the Glea-
on score for each patient. However, our pathologists confirm that
t least since 2007 most patients were assessed using the 2005 ISUP
leason system modifications. Lastly, the limited follow up in our
eries does not allow for an evaluation of the biochemical recurrence
r prognosis after radical prostatectomy in our patients, which is the
ost important issue in PCa rather than the presence of unfavorable
athological features.
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Conclusions
Based on future projection models, the incidence and mortality rates
from prostate cancer in North Africa and the Middle East are on the
rise. PSA-screening appears to be inevitable in this region in order to
improve migration of the currently more advanced diseases to more
low-risk organ-confined diseases, and to identify more patients who
would be eligible for conservative treatment approaches such as
AS and FT. The contemporary Epstein criteria, even when assessed
based on extended 10–18 core prostate biopsy, may underestimate
the real significance of PCa in North African patients in as many
as 43%. Currently, there is an ongoing need for identifying new
prognostic tools (e.g. MP-MRI, molecular markers) to improve the
pre-treatment prediction of Ins-PCa. So, caution is advised when
the decision for AS or focal ablative therapies is based solely on
these criteria in North African men.
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